AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 261 min read$TXG

SULIMAN SHEHNAAZ sold $140K of TXG

SULIMAN SHEHNAAZ sold 2,207 shares of 10x Genomics, Inc. (TXG) at an average of $63.65 ($62.73–$63.97, $0.14M total) across 2 trades on 2026-08-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · SULIMAN SHEHNAAZ
Published Aug 26, 2026, 8:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TXG
Neutral
high confidence
Mentioned
$TXG
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TXGNeutralLow
01

Why it matters

The transaction is routine and unlikely to affect the stock's short‑term trajectory.

02

Market read

Low relevance; small insider sale with no immediate market impact.

03

What to watch

Potential future dilution or upcoming corporate actions not disclosed.

Relevance 3/10Novelty 4/10Timing: filing date 2026‑08‑26

Background

SEC Form 4 filing reporting a director's sale of 2,207 shares of 10x Genomics.

Company-level read

Ticker impact

$TXGNeutralHigh confidence
Context

Director Suliman Shehnaaz sold $140K of 10x Genomics shares via a 10b5‑1 plan on 2026‑08‑24.

Expected impact

No significant impact expected.

Evidence & confidence

Sale size is small relative to market cap and disclosed via routine pre‑arranged plan.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider sell could signal concerns, but size is trivial.

Key entities

  • company
    10x Genomics, Inc.

    Biotech firm listed on NASDAQ under ticker TXG.

  • person
    Suliman Shehnaaz

    Director of 10x Genomics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TXG insider trading history →

Related articles

SEP 24
$TXGMed

TXG Stock Jumps As AI Partnership And Legal Win Shift Outlook

10x Genomics Inc. (TXG) stock rose 13.01% on September 24, 2026, driven by an AI partnership with Lunit and a patent win against Qiagen. The company's stock has surged from $59.98 to $84.11 over recent weeks. TXG reported $642.8M in revenue with strong gross margins but negative operating margins. Analysts have mixed views, with price targets ranging from $60s to $70.

timothysykes.com3 min
SEP 24
$TXGMed

TXG Stock Jumps As AI Deal And Legal Win Shift Momentum

10x Genomics Inc. (TXG) stock rose 12.23% on September 24, 2026, driven by investor optimism over AI partnerships and a legal win. The company's stock has increased over 35% in under a month, reaching $84.91. TXG reported $151M in quarterly revenue with a 70% gross margin but remains unprofitable. Analysts have mixed views, with targets around $70, while traders focus on momentum and future growth potential.

timothysykes.com3 min
SEP 3
$TXGMed

10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?

10x Genomics (TXG) has risen 84% in 3 months, driven by consumables growth and Atera demand. Q2 2026 consumables revenue increased 7% YoY, with Single Cell up 3% and Spatial up 16%. Management raised 2026 revenue guidance to $610M-$630M. However, instrument sales fell 47.2% YoY, and the company reported a $19.6M operating loss. TXG trades at 11.9X forward sales, a premium to peers.

tradingview.com3 min
AUG 18
$TXGMed

10x Genomics (TXG) Sees Strong Early Orders for New Atera Platform

10x Genomics (NASDAQ:TXG) reported Q2 revenue of $151m, including a $1.6m Takara settlement; excluding it, revenue was $149.4m, up 3% YoY. Atera booked orders already exceed planned 2026 shipments (~40 units). Cash rose to $552m and gross margin to 74%. Full-year revenue guidance raised to $610m-$630m; instrument revenue fell 47% YoY.

yahoo.com3 min
AUG 14
$TXGMedAI 9/10

10x Genomics (TXG) Q2 2026 Earnings Call Transcript

10x Genomics (TXG) reported Q2 2026 revenue of $151.0 million, up 3% YoY excluding non-recurring patent settlement revenue. Gross margin was 74%. FY2026 revenue guidance is $610 million to $630 million. Booked Atera orders exceed the 2026 shipment target of 40 units, with capacity as the constraint. Net loss was $17.9 million.

fool.com10 min